ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: Indeed, maintenance CML LSCs in TKI-resistant patients suggest that CML LSCs contribute to drug resistance through survival mechanisms that are not entirely reliant on BCR-ABL activation.